$EIGR News
Last published 2y ago
- 2y agoEIGREiger BioPharmaceuticals Files for Voluntary Chapter 11 ProtectionGlobeNewswireAnnounces "Stalking Horse" Agreement for the Sale of Zokinvy® (lonafarnib) Patient Access to Zokinvy® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger
- 2y agoEIGREiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock SplitPR NewswireEiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) (the "Company"), a commercial-stage biopharmaceutical company focused on the development of innovative...
- 2y agoCUTREIGRCutera Appoints Stephana Patton as Chief Legal OfficerBusiness WireCutera, Inc. (NASDAQ:CUTR) ("Cutera" or the "Company"), a leading provider of aesthetic and dermatology solutions, is pleased to announce the appointment of Stephana Patton, Ph.D., J.D. as Chief Legal Officer, effective
- 3y agoEIGREiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdatePR NewswireEiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for...
- 3y agoEIGREiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis DeltaPR NewswirePALO ALTO, Calif., Sept. 12, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases,
- 3y agoEIGREiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment ConferencePR NewswirePALO ALTO, Calif., Sept. 5, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases,
- 3y agoEIGREiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdatePR NewswireResources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align
- 3y agoEIGREiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEOPR NewswirePrioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indicationsActive discussions underway with potential partners to advance late-stage virology programsReduction in workforce executed to align
- 3y agoEIGREiger BioPharmaceuticals to Host Business Update Call TomorrowPR NewswireCompany to host conference call and live webcast on Thursday, June 29, at 8:30 am ETPALO ALTO, Calif., June 28, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical
- 3y agoEIGREiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business UpdatePR NewswirePhase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting with FDA in Q2Phase 3 HDV LIMT-2 (peginterferon lambda) Study: Complete Randomization in Q2Phase 3 HI AVANT (avexitide) Program: Startup Activities
- 3y agoEIGREiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)PR NewswirePALO ALTO, Calif., May 3, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV)
- 3y agoEIGREiger BioPharmaceuticals Strengthens Management Team with New AppointmentsPR NewswireWilliam G. Kachioff appointed as Chief Financial OfficerJames A. Vollins appointed as General Counsel, Chief Compliance Officer and Corporate SecretaryPALO ALTO, Calif., April 13, 2023 /PRNewswire/ -- Eiger
- 3y agoEIGREiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatePR NewswirePhase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting Planned by End of Q2Phase 3 HDV LIMT-2 (peginterferon lambda) Study: On Track to Complete Randomization by End of Q2Phase 3 HI AVANT (avexitide) Program:
- 3y agoEIGRNew England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19PR Newswire- Phase 3 TOGETHER data showed early treatment with a single dose of peginterferon lambda (Lambda) in patients with mild-to-moderate COVID-19 infections resulted in significantly decreased clinical events - Lambda
- 3y agoEIGREiger BioPharmaceuticals Announces Leadership ChangeBusiness WirePresident and CEO David A. Cory resigns from the company effective immediately Dr. David Apelian named Interim CEO Eiger BioPharmaceuticals, Inc. ("Eiger" or "the company") (NASDAQ:EIGR), a commercial-stage
- 3y agoEIGREiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary EndpointPR Newswire- Lonafarnib/ritonavir response rate of 10.1% (p=0.0044)- Lonafarnib/ritonavir in combination with peginterferon alfa response rate of 19.2% (p<0.0001)- Peginterferon alfa comparator arm, included for contribution
- 3y agoEIGREiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022PR NewswireLive Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif., Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of
- 4y agoEIGREiger BioPharmaceuticals to Participate in Upcoming Investor ConferencesPR NewswirePALO ALTO, Calif., Nov. 8, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus
- 4y agoEIGREiger BioPharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business UpdatePR NewswirePhase 3 HDV D-LIVR (lonafarnib-based regimens) Study Topline Data in DecemberPhase 3 HDV LIMT-2 (peginterferon lambda) Study Activating Sites and Enrolling PatientsPhase 3 Congenital Hyperinsulinism Avant (avexitide)
- 4y agoEIGREiger BioPharmaceuticals to Host Conference Call for Third Quarter 2022 Financial Results and Business Update on Thursday, November 3PR Newswire- Live Conference Call and Webcast at 4:30 PM ET - PALO ALTO, Calif., Oct. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development
- 4y agoEIGREiger BioPharmaceuticals to Present at the H.C. Wainwright Third Annual Hepatitis B Virus (HBV) Virtual ConferencePR NewswirePALO ALTO, Calif., Oct. 11, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus
- 4y agoEIGREiger BioPharmaceuticals Provides Update on Plans for Emergency Use Authorization Application Following FDA FeedbackPR NewswirePALO ALTO, Calif., Oct. 5, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, tod
- 4y agoEIGREiger BioPharmaceuticals to Present at the 2022 Ladenburg Thalmann Healthcare ConferencePR NewswirePALO ALTO, Calif., Sept. 22, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, to
- 4y agoEIGREiger BioPharmaceuticals Provides Update on Status of Planned Peginterferon Lambda COVID-19 Emergency Use Authorization ApplicationPR NewswirePALO ALTO, Calif., Sept. 6, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, tod
- 4y agoEIGREiger BioPharmaceuticals to Participate in Three Upcoming Investor ConferencesPR NewswirePALO ALTO, Calif., Sept. 1, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, to
- 4y agoEIGREiger BioPharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business UpdatePR NewswireActive Dialogue with FDA on Potential Peginterferon Lambda COVID-19 EUA Application Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Planned by Year End Phase 3 Congenital Hyperinsulinism AVANT (avexitide) Program Initiated Approval of Zokinvy in E
- 4y agoEIGREiger BioPharmaceuticals to Host Conference Call for Second Quarter 2022 Financial Results and Business Update on Thursday, August 4PR Newswire- Live Conference Call and Webcast at 4:30 PM ET - PALO ALTO, Calif., July 28, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for h
- 4y agoEIGREiger Receives European Approval for Zokinvy® (lonafarnib) for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid LaminopathiesPR NewswireFirst and only treatment approved in Europe to treat Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies1 Extended life by an average of 4.3 years in children and young adults with HGPS2 Now approved for use in 30 Eu
- 4y agoEIGREiger Appoints Senior Human Resources and Organizational Executive Lisa Kelly-Croswell to Board of DirectorsPR NewswirePALO ALTO, Calif., July 18, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other seriou
- 4y agoEIGREiger BioPharmaceuticals Announces Results from Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022PR NewswirePALO ALTO, Calif., June 27, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other seriou
- 4y agoEIGREiger BioPharmaceuticals Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia After Gastrointestinal SurgeriesPR Newswire- Data presented in oral presentation at ENDO 2022 on June 11 - Avexitide significantly reduced the number of hypoglycemia events and the amount of time spent in hypoglycemia - Study included patients who had undergone gastric bypass, vertical
- 4y agoEIGREiger BioPharmaceuticals Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022PR Newswire- Presentations Showcase Eiger's Innovative Therapies for Hepatitis Delta Virus PALO ALTO, Calif., June 8, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of
- 4y agoEIGREiger BioPharmaceuticals Enters into $75M Term Loan Agreement and $5M Stock Purchase Agreement with Innovatus Capital Partners to Refinance Existing Debt Facility and Further Strengthen Cash Position Ahead of Key MilestonesPR NewswireEiger nets approximately $11M after retiring its existing debt facility Immediately bolsters cash position and provides access to an additional $35M in non-dilutive capital on clinical and regulatory milestones PALO ALTO, Calif., June 7, 2022 /PRNews
- 4y agoEIGREiger BioPharmaceuticals to Present at the Jefferies Global Healthcare ConferencePR NewswirePALO ALTO, Calif., June 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious
- 4y agoEIGREiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid LaminopathiesPR NewswireIf authorized, Zokinvy® (lonafarnib) will be the first and only treatment approved in Europe to treat Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies - collectively known as progeria. CHMP based its opinion on the
- 4y agoEIGREiger BioPharmaceuticals to Present at H.C. Wainwright Global Investment ConferencePR NewswirePALO ALTO, Calif, May 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious d
- 4y agoEIGRTYO:4563Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® (lonafarnib) in JapanPR NewswirePALO ALTO, Calif. and OSAKA, Japan, May 10, 2022 /PRNewswire/ -- Eiger Biopharmaceuticals Inc. ((", Eiger", , NASDAQ:EIGR) and AnGes Inc. ((", AnGes", , TYO:4563) today announced that the companies entered into an agreement for the regulatory approval, m
- 4y agoEIGREiger BioPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business UpdatePR NewswirePeginterferon lambda COVID-19 EUA Application to be Submitted in Q2 2022 Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Anticipated by Year End Zokinvy® (lonafarnib) CHMP Opinion Expected in Q2 2022 Phase 3 Avexitide Congenital Hyperinsulinism P
- 4y agoEIGREiger BioPharmaceuticals Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)PR NewswirePALO ALTO, Calif., April 29, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other seriou
- 4y agoEIGREiger Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and Initiation of Phase 3 ProgramPR Newswire- Phase 2 study demonstrating avexitide significantly reduced hypoglycemia in children with congenital hyperinsulinism published in Diabetes Care- Eiger plans to initiate avexitide Phase 3 registrational program by year-end 2022 PALO ALTO, Calif.,
- 4y agoEIGREiger BioPharmaceuticals to Host Conference Call for First Quarter 2022 Financial Results and Business Update on Thursday, May 5PR Newswire- Live Conference Call and Webcast at 4:30 PM ET - PALO ALTO, Calif., April 21, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to
- 4y agoEIGREiger BioPharmaceuticals Strengthens Leadership Team with New Executive AppointmentsPR NewswireChris Kurtz Appointed Chief Technical Officer Sarah Mathieson Appointed Senior Vice President, Corporate Affairs PALO ALTO, Calif., April 18, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical comp
- 4y agoEIGREiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER StudyPR NewswireSecond largest study to date in COVID-19 outpatients (N=1,936) Highly superior compared to placebo, with a probability of superiority of 99.91% on the primary endpoint 60% reduced risk of COVID-19-related death Primary endpoint achieved across mul
- 4y agoEIGREiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 TOGETHER Study Results of Peginterferon Lambda for COVID-19 on Thursday, March 17, 2022PR NewswireLive Conference Call and Webcast at 5:30 AM Pacific / 8:30 AM Eastern PALO ALTO, Calif., March 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovat
- 4y agoEIGREiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business UpdatePR NewswirePALO ALTO, Calif., March 10, 2022 /PRNewswire/ -- Phase 3 COVID-19 TOGETHER (Lambda) Study Data in March 2022 Phase 3 HDV D-LIV
- 4y agoEIGREiger BioPharmaceuticals to Host Conference Call for Fourth Quarter & Full Year 2021 Financial Results and Business Update on Thursday, March 10PR NewswirePALO ALTO, Calif., Feb. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other seriou
- 4y agoEIGROnce Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection - NCT05229991ClinicalTrials.govViral load change, HDV RNA levels below LLOQ
- 4y agoEIGREiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and MilestonesPR NewswirePALO ALTO, Calif., Jan. 6, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious
- 4y agoEIGREiger BioPharmaceuticals to Present at H.C. Wainwright BioConnect 2022 Virtual ConferencePR NewswirePALO ALTO, Calif., Jan. 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious
- 4y agoEIGREiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) InfectionPR NewswirePALO ALTO, Calif., Dec. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serio